Gsk Share Discussion Threads

[lippy4] 12/11/2024 22:38

how can we have a mp who has two passports which tells you he is not committed to this country and that is lammy whom i find him totally unsuitable to represent this country whats left of it..

[tradermichael] 12/11/2024 15:37

Self-fulfilling ....

[dope007] 12/11/2024 14:24

He's better than that. Trump loves us

[montyhedge] 12/11/2024 14:16

He will like the U.K. if that idiot Lammy goes.

[dope007] 12/11/2024 13:10

trump loves the UK. EU not so much. We'll be fine

[tradermichael] 12/11/2024 12:36

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that includes a preclinical small molecule initially targeting Parkinson’s disease.

The British Big Pharma will take on responsibility for Vesalius’ small molecule, with the option to move forward Vesalius-identified intervention point programs in Parkinson’s and another unnamed neurodegenerative condition, according to a Nov. 12 release. GSK will retain rights over all development and commercial activities.


In return, Vesalius will receive $80 million in upfront and equity payments and has the chance to make up to $570 million in potential milestones for the preclinical small molecule program, plus royalties.



The Cambridge, Massachusetts-based biotech could also bring in additional biobucks and royalties tied to each new intervention point resulting from the deal. The partners did not disclose the potential total value of the entire pact.

[scepticalinvestor] 12/11/2024 09:32

Not GSK, all UK stocksEasiest market to short. Even zimbabwe has a more growth focused gov than starmer and coNo dbt reeves will start introducing a ban on shorting

[supermarky] 12/11/2024 09:06

Not much interest in buying before the divi Gsk so unloved at the moment.I am holding firm and may top up at some point. Sitting on my hands right now.

[dplewis1] 12/11/2024 08:08

Jefferies cuts to hold from buy. Target price to 1,525p from 2,000p

[xtrmntr] 08/11/2024 19:52

GSK (GSK) used its third-quarter trading update to draw a definitive line under the damaging litigation around its now discontinued heartburn medicine Zantac, by agreeing a settlement earlier in October that will see claims settled for a total of $2.2bn (£1.68bn). While this overshadowed the results, the pharmaceutical company was able to reaffirm its guidance for the year. Management expects turnover growth of 7-9 per cent; core operating profit growth of 11-13 per cent and core earnings per share (EPS) growth of 10-12 per cent, with GSK expected to deliver broadly around the middle of the existing ranges. The third-quarter performance was generally acceptable, with turnover growing by 2 per cent to £8bn, with a notable increase in core EPS, which was up 5 per cent to 49.7p. The core operating profit also increased by 5 per cent to £2.76bn, which excludes the impact of large one-off costs. Once these are included then reported quarterly operating profits dropped by 86 per cent. Analysts were generally sceptical about the company's vaccines performance. Sheena Berry, healthcare equity analyst at Quilter Cheviot noted: "The performance of key vaccines was underwhelming. Shingrix and Arexvy saw declines of 7 per cent and 72 per cent, respectively, largely due to changes in ACIP [Advisory Committee on Immunization Practices, part of the CDC] guidelines and the prioritisation of Covid vaccines in the US".Chief executive Emma Walmsley said: "Our pipeline continues to strengthen, with 11 positive phase III trials reported so far this year and we are currently planning launches for five major new product approval opportunities next year... All this means we are on track to deliver our 2024 guidance, and we are even more confident in our 2026 and 2031 outlooks."

[halfpenny] 08/11/2024 16:20

Further falls to come

[dope007] 08/11/2024 08:52

Dartboard and blindfold

[tradermichael] 08/11/2024 08:35

Barclays said 1725p in May ...... short-termism with this 'broker'?

[dplewis1] 08/11/2024 08:13

Barclays cuts target price to 1450p from 1550p

[tradermichael] 07/11/2024 10:33

15p next week

[supermarky] 07/11/2024 09:58

what the divi 4.4% ?

[supermarky] 07/11/2024 09:57

gsk definitely on the naughty step at the moment. Xd next week.

[jubberjim] 07/11/2024 06:46

I was anticipating a trump victory and while not too unhappy at the thought of the rally in shares in the aftermath was not expecting the markets to take such a dim view here and in europe .

Looks like I jumped in too soon with this one from what I am reading on the internet and comments passed.

I had put it all down to Astra Zenecas tribulations but it seems as if the infection and fear has spread.

Just have to tough it out until things become clearer and I can get some direction, In the meantime the dividend pours some salve on the wound but I will have to suffer the pain for some time to come.

Be good and be lucky

[dr biotech] 06/11/2024 21:12

Can watch the clip yourself. I’d expect more legal issues and similar cases to Zantac if RFK gets the gig.


hxxps://youtu.be/vfLZOkn0chc?si=_7RBCZG-mN83hD_-

[geckotheglorious] 06/11/2024 20:41

TM

You do realise all of that was disingenuous bollux right. Peddled by a biased left wing MSM..

It's been a great day

A whitewash

A red wave.

Very satisfying.

[tradermichael] 06/11/2024 15:49

At this rate I'd expect some buying for the dividend next week - xd 14 Nov (15p/share)